Prentiss Smith & Co’s AbbVie ABBV Stock Holding History

Prentiss Smith & Co’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$977K	Hold	3,883	–	–	0.54%	38
2026 Q1	$845K	Sell	3,883 -235	-6%	-$52.1K	0.49%	40
2025 Q4	$941K	Sell	4,118 -147	-3%	-$33.5K	0.56%	37
2025 Q3	$988K	Hold	4,265	–	–	0.56%	41
2025 Q2	$792K	Hold	4,265	–	–	0.47%	45
2025 Q1	$894K	Sell	4,265 -235	-5%	-$45.7K	0.58%	44
2024 Q4	$800K	Hold	4,500	–	–	0.52%	44
2024 Q3	$889K	Hold	4,500	–	–	0.57%	42
2024 Q2	$772K	Sell	4,500 -147	-3%	-$24.4K	0.54%	42
2024 Q1	$846K	Sell	4,647 -405	-8%	-$69.8K	0.6%	39
2023 Q4	$783K	Sell	5,052 -623	-11%	-$90.8K	0.58%	37
2023 Q3	$846K	Sell	5,675 -235	-4%	-$34.5K	0.62%	35
2023 Q2	$796K	Hold	5,910	–	–	0.6%	36
2023 Q1	$942K	Hold	5,910	–	–	0.7%	34
2022 Q4	$955K	Sell	5,910 -370	-6%	-$56.7K	0.87%	25
2022 Q3	$843K	Hold	6,280	–	–	0.75%	31
2022 Q2	$962K	Hold	6,280	–	–	0.74%	33
2022 Q1	$1.02M	Hold	6,280	–	–	0.61%	37
2021 Q4	$850K	Sell	6,280 -250	-4%	-$29.5K	0.4%	48
2021 Q3	$704K	Hold	6,530	–	–	0.36%	46
2021 Q2	$736K	Hold	6,530	–	–	0.35%	45
2021 Q1	$707K	Hold	6,530	–	–	0.36%	46
2020 Q4	$700K	Sell	6,530 -927	-12%	-$89.1K	0.33%	46
2020 Q3	$653K	Buy	7,457 +2,480	+50%	+$233K	0.34%	44
2020 Q2	$489K	Hold	4,977	–	–	0.3%	43
2020 Q1	$379K	Sell	4,977 -650	-12%	-$55.4K	0.26%	50
2019 Q4	$498K	Sell	5,627 -315	-5%	-$26.2K	0.32%	43
2019 Q3	$450K	Hold	5,942	–	–	0.3%	45
2019 Q2	$432K	Hold	5,942	–	–	0.28%	48
2019 Q1	$479K	Buy	5,942 +200	+3%	+$16.4K	0.3%	45
2018 Q4	$529K	Hold	5,742	–	–	0.33%	40
2018 Q3	$543K	Hold	5,742	–	–	0.31%	43
2018 Q2	$532K	Hold	5,742	–	–	0.32%	43
2018 Q1	$543K	Buy	5,742 +92	+2%	+$10.1K	0.28%	48
2017 Q4	$546K	Sell	5,650 -1,300	-19%	-$123K	0.27%	52
2017 Q3	$618K	Hold	6,950	–	–	0.36%	38
2017 Q2	$504K	Hold	6,950	–	–	0.26%	49
2017 Q1	$453K	Sell	6,950 -299	-4%	-$18.8K	0.26%	51
2016 Q4	$454K	Buy	7,249 +299	+4%	+$18.3K	0.28%	44
2016 Q3	$438K	Sell	6,950 -168	-2%	-$10.9K	0.24%	53
2016 Q2	$441K	Buy	7,118 +168	+2%	+$10.2K	0.25%	50
2016 Q1	$397K	Sell	6,950 -485	-7%	-$27K	0.23%	56
2015 Q4	$440K	Sell	7,435 -21,272	-74%	-$1.23M	0.23%	53
2015 Q3	$1.56M	Sell	28,707 -2,362	-8%	-$154K	0.87%	27
2015 Q2	$2.09M	Sell	31,069 -4,263	-12%	-$278K	1.03%	28
2015 Q1	$2.07M	Sell	35,332 -2,683	-7%	-$162K	0.99%	26
2014 Q4	$2.49M	Buy	38,015 +2,026	+6%	+$128K	1.16%	24
2014 Q3	$2.08M	Sell	35,989 -2,230	-6%	-$124K	1.04%	26
2014 Q2	$2.16M	Sell	38,219 -1,490	-4%	-$78.2K	1.1%	24
2014 Q1	$2.04M	Sell	39,709 -3,460	-8%	-$175K	1.08%	24
2013 Q4	$2.28M	Sell	43,169 -16,277	-27%	-$800K	1.19%	22
2013 Q3	$2.66M	Sell	59,446 -1,230	-2%	-$54.5K	1.38%	20
2013 Q2	$2.51M	Buy	+60,676	New	+$2.65M	1.3%	22

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Prentiss Smith & Co's ABBV Position: Q2 2026 in Review

Prentiss Smith & Co held its AbbVie (ABBV) position steady in Q2 2026 at 3,883 shares worth $977K. The position accounts for 0.54% of the portfolio, ranked #38.

Prentiss Smith & Co first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. The position peaked at $2.66M in Q3 2013. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Prentiss Smith & Co held 3,883 shares of AbbVie worth $977K as of Q2 2026.
Prentiss Smith & Co left its AbbVie share count unchanged in Q2 2026.
AbbVie made up 0.54% of Prentiss Smith & Co's portfolio in Q2 2026, its #38 holding.
Prentiss Smith & Co first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
Prentiss Smith & Co's AbbVie position peaked at $2.66M in Q3 2013.
4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Prentiss Smith & Co's 13F filing for Q2 2026, filed 30 Jul 2026.